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Available online 27 January 2016AbstractMetastasis is the leading cause of mortality in patients with breast cancer. In triple-negative breast cancer, high recurrence rates, increased
invasive capacity of cells, and their aggressive ability to metastasize at secondary sites dictate patient survival. The Naþ/Hþ exchanger isoform 1
(NHE1) plays a critical role in controlling the metastatic potential of these cells. Its activity results in an elevation of intracellular pH and in
extracellular acidification, a key step in the establishment of the tumor microenvironment. Here, we describe assays for characterization of Naþ/
Hþ exchanger activity and its related downstream physiological effects on triple-negative breast cancer cells. Naþ/Hþ exchanger activity can be
routinely and rapidly measured in live cells with a fluorometric assay that assesses changes in intracellular pH. Characterization of downstream
cell effector function as a result of Naþ/Hþ exchanger activation can be evaluated by measuring directed cell migration and invasion. Cell
migration is assessed with wound-healing assays, where a gap is introduced in a confluent monolayer of cells and the rate of gap closure is
measured over time. Cell invasion is assessed in the short-term by transwell invasion assays that track cell movement through an extracellular
matrix. Long-term invasiveness, growth and proliferation can be assessed with 3-D invasion assays using transwell inserts fitted with specialized
scaffolds optimized for 3-D cell culture. Taken together these assays provide powerful tools for testing the effects of altering Naþ/Hþ exchanger
activity with chemical inhibition on the metastatic capacity of breast cancer cells.
© 2016 The Authors. Published by Elsevier B.V. on behalf of Socie´te´ Franc¸aise de Biochimie et Biologie Mole´culaire (SFBBM). This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Breast cancer is the most commonly diagnosed cancer
among women [1], and it is the resulting metastasis that is the
main cause of patient fatality [2,3]. Triple-negative breast
cancers in particular (negative for estrogen and progesterone
receptors and human epidermal growth factor receptor-2
(HER2)) are the most problematic. They tend to be more
aggressively metastatic and have high recurrence rates asso-
ciated with resistance to standard chemotherapy treatments.
This makes their characterization and development of treat-
ments to stop metastasis most imperative, particularly since
there are no therapies uniquely targeted toward this clinical
breast cancer subtype.
A common property of tumor cells is intracellular alka-
linization due to the activity of the membrane protein Naþ/Hþ
exchanger (NHE) [4]. NHE is present in the plasma membrane
and removes 1 intracellular Hþ in exchange for 1 extracellular
Naþ [4e8]. The increased pHi, which is mediated by NHE1
(NHE isoform 1), is associated with the proliferation and
transformation tumor cells [8e18]. In particular, recently
NHE1 has been shown to play a critical role of in the growth
and metastasis of triple-negative breast cancer cells [19e23].
It is thought that, in addition to affecting intracellular pH,
activity of NHE1 acidifies the extracellular microenvironment
of tumor cells [8,17,18] which facilitates the digestion and
remodeling of the extracellular matrix [18,24,25], critical to
metastasis.
We have recently shown that disruption of the NHE1 gene
inhibits the ability of MDA-MB-231 breast cancer cells to
form in vivo xenograft tumors in athymic nude mice [19].
Also, NHE1 inhibition had a synergistic effect with the
commonly used chemotherapy agent paclitaxel, resulting in a
dramatic decrease in migratory and invasive potential of breast
cancer cells. While these results marked a novel inroad in the
fight against breast cancer, much remains to be done and
NHE1 remains a viable research target in this regard. It is of
note that NHE1 is also a clinical target in ischemic heart
diseases and heart hypertrophy. However, the use of NHE1
inhibitors in the cardiovascular clinical setting has been
disappointing with detrimental side effects [26,27], and the
development of new NHE1 inhibitors may be called for. In any
case, NHE1 inhibitor development for use in the cardiovas-
cular or the cancer setting will require careful analysis of their
inhibitory behavior and downstream effects.The purpose of this report is to outline and make readily
accessible to other investigators assays for NHE1 activity and
for downstream effects of NHE1 on triple-negative breast
cancer (TNBC) cell behavior. The downstream behavior in-
cludes cell migration and invasion. It is hoped that this in-
formation will facilitate more active research into this area,
leading to a more rapid development of clinical treatments to
reduce metastasis in triple-negative breast cancer.
2. Materials and methods2.1. Materials20, 7-bis (2-carboxyethyl)-5(6) carboxyfluorescein acetox-
ymethyl ester (BCECF-AM) was from Molecular Probes, Inc.
(Eugene, OR). All the other chemicals used were of analytical
grade and were acquired from Fisher Scientific (Ottawa, ON,
Canada), Sigma (St. Louis, MO, USA) or BDH (Toronto, ON,
Canada). Nigericin was obtained from multiple sources
including Sigma and Caymen Chemicals (Ann Arbor, Michi-
gan, USA). Coverslips were Red Label® Micro Cover Glasses
from Thomas Scientific (Swedesboro, N.J., USA). Fluorom-
eter cuvettes were made of polymethacrylate (Sigma).2.2. Cell lines and culture conditionsParental MDA-MB-231 cells were authenticated by DNA
analysis (DDC Medical, Ohio). They showed >95% homology
to the ATCC STR profile. Culture conditions were as described
earlier [19]. Briefly, all cells were cultured in high-glucose
(4500 mg/L) modified DMEM (HyClone) supplemented with
10% fetal calf serum (HyClone), 10 mM HEPES, and
1000 units/ml penicillin/streptomycin (Gibco) under 5% CO2,
37 C and high humidity. Starvation media was supplemented
with 0.2% serum but otherwise identical in composition.
2.2.1. Measurement of NHE1 activity
NHE1 activity was determined using a PTI Deltascan
spectrofluorometer [19,28,29]. Experiments are described
briefly and details of solutions and additions are contained in
Table 1. Part A can be considered to be growth of MDA-MB-
231 cells on coverslips and loading with the fluorescent dye
BCEC-AM. Cells are grown in normal growth medium as
described above. Two sterilized coverslips (Thomas® Red
Label®Micro Cover Glasses) were previously added to 35 mm
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80e90% confluent. BCECF-AM (20,70-bis(2-carboxyethyl)-
5(6) carboxyfluorescein-acetoxymethyl ester) (Molecular
Probes Inc., Eugene, OR, USA) is added to a final concen-
tration of 2.5 mg/ml (1 ml of 1 mg/ml stock in DMSO), is
added to the cells while the cells are in 400 ml normal tissue
culture media (in the absence of serum). The cells are main-
tained at 37 C for approximately 20 min. During this incu-
bation period BECEF-AM is de-esterified and becomes
trapped within the cell [30,31]. It then fluoresces dependent
upon intracellular pH (described below). BCECF-AM is stored
as a 1 mg/ml stock in DMSO at 20 C in a darkened
container.
2.2.2. Acute acidification and recovery
Part B is the measurement of intracellular pH changes in
the cell, upon an induced, acute acid load. The outline is
described below, with details included in Table 1. One of the
pair of coverslips is removed from the petri dish. It is manually
transferred to a Teflon coverslip holder that has a thin grove on
the side in which the coverslip is wedged. The coverslip holder
was made in-house and designed to fit in a standard spectro-
fluorometer cuvette. It is also designed to hold the coverslip
such that it is at approximately 45 to the excitation lightTable 1
Protocol for measurement of pHi in MDA-MB-231 cells on coverslips. Cells are gr
controlled cuvette with constant stirring.
Step Parameter Value
1 Equilibration 2.5 ml
2 Ammonium Cl 30 ml
3 Acidification 2.5 ml
4 Recovery 2.5 ml
5 pH Calibration 2.5 ml
6 pH Calibration 2.5 ml
7 pH Calibration 2.5 ml
1Normal Buffer.
135 mM NaCl.
5 mM KCl.
1.8 mM CaCl2.
1 mM MgSO4.
5.5 mM Glucose.
10 mM Hepes.
Warm solution to 37 C and adjust pH of warm solution to 7.3 using KOH and H
2Naþ-free buffer.
135 mM N-Methyl glucamine.
5 mM KCl.
1.8 mM CaCl2.
1 mM MgSO4.
5.5 mM Glucose.
10 mM Hepes.
Warm solution to 37 C and adjust pH of warm solution to 7.3 using KOH and H
3pH Calibration Buffer.
5 mM N-Methyl glucamine.
135 mM KCl.
1.8 mM CaCl2.
1 mM MgSO4.
5.5 mM Glucose.
10 mM Hepes.
Warm solutions to 37 C and adjust pH of warmed solution to 6, 7, and 8 using K
4Nigericin. 10 mM stock in ethanol, stored in 20 C. 2.5 ml is added to 2.5 of psource, and does not reflect the exciting light source directly
into the photometer measuring emission. It has a spacer on the
bottom allowing for stirring of the surrounding solution. The
coverslip is placed in a solution of “normal” buffer containing
135 mM NaCl (Table 1, Fig. 1) for 2e3 min. This is a simple
equilibration stage. Next, a series of changes or additions are
used to induce an acute acid load. All solutions are kept at
37 C. Ammonium chloride is next (step 2) added from a
concentrated stock solution. This initially alkalinizes the cell
and after approximately 3 min, the pH returns to near resting
pHi (Fig. 1). The amount of ammonium chloride can be
increased or decreased to vary the level of acidification later
produced. This is followed by a brief rinse and 20e30 s stay in
sodium free buffer (step 3). The rapid removal of extracellular
ammonium chloride shifts the intracellular equilibrium to-
wards acid production, resulting in a large acid load in the cell
(Fig. 1). pHi may decline to approximately 6.0. (The sequence
of events leading to acidification is outlined in Fig. 1). Once
the cells are acidified, they are returned to sodium-containing
buffer to demonstrate Naþ/Hþ exchanger activity (step 4). The
initial rate of recovery in the first 20 s is measured after re-
covery begins. The recovery can be allowed to continue for
several minutes though the rate of alkalinisation declines with
increasing pHi.own on coverslips as describe in the text. They are placed in a thermostatically
Description
“Normal1” sodium containing buffer for equilibration
Final of 30 mM (2.5 M Stock), 3 min
Sodium free2 buffer, 30 s
“Normal1” sodium containing buffer
3pH 8.0 Calibration Buffer þ 4nigericin
3pH 7.0 Calibration Buffer þ 4nigericin
3pH 6.0 Calibration Buffer þ 4nigericin
Cl.
Cl.
OH and HCl.
H.
Fig. 1. Naþ/Hþ exchanger activity in MDA-MB-231 cells. Changes in intra-
cellular pH (pHi) in response to acid loading induced by ammonium chloride.
An example of trace illustrating the changes in pHi from an acute acid load
followed by recovery and pHi calibration is shown. Periods of NH4Cl, NaCl
and Na-free solution are indicated and correspond with Table 1. Step 1 is an
equilibration step allowing the cells to recovery from loading of BCECF. In
Step 2, ammonium chloride is added. This initially alkalinizes the cell as
uncharged NH3 is more permeable than the other cations. This makes an
equilibrium shifted towards NH4
þ in the cell. Over a period of a few minutes,
the equilibrium balances with further diffusion. In step 3, external ammonium
chloride is removed and replaced with a sodium-free buffer. NH3 diffuses out
rapidly, shifting the intracellular equilibrium to produce protons (Hþ). This
solution is then changed to sodium-containing solution (Step 4), which induces
the activity of the Naþ/Hþ exchanger. pH calibration (Steps 5e7) is with
nigericin-containing solutions at specific pH's. Nigericin is a Hþ, Kþ-iono-
phore that equilibrates external with internal pH.
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For every coverslip of cells, a pH calibration curve is made
which is then used to convert the emissions to intracellular
pH28. After the final recovery (step 4 above) cells are trans-
ferred to 3 successive pH calibration buffers (Table 1, Fig. 1).
In each pH calibration buffer, 2.5 ml of nigericin is added to a
final concentration of 10 mM. Readings are taken at each pH.
Cells are allowed to remain at the first pH calibration buffer
for 2e3, and ½-1 min each successive pH calibration solution.
2.2.4. pHi measurement
Intracellular pH measurement is via dual excitation, single
emission ratio. This helps ensure a measurement that is in-
dependent of the amount of cells or the amount of BCECF that
has been taken up by the cells. Excitation is at wavelengths
440 and 502.5 nm. Emission is at 528.7 nm. Slit widths of
excitation should be restricted as much as possible, ideally less
than 5 nm for excitation. Excitation at 440 nm is at the iso-
sbestic point, and results in an emission that is independent ofpHi, while excitation at 502.5 nm will cause an emission that
is dependent on pHi. Taking the ratio of these two therefore
gives a reading that varies with pHi and is not dependent on
dye concentration or cell number. Instrumentation for mea-
surement of emission can vary.
2.2.5. General considerations
An experienced user can generally carry out two indepen-
dent assays on two machines simultaneously, with the timing
of the assays slightly staggered. Up to 24 assays can be done in
one day. We have found that inclusion of a small stirring bar
below the cuvette greatly improves readings. Anomalous
readings can be caused by several factors. Loss of cells on the
coverslip can give too weak a signal. However, this has never
been a problem with this cell type. An alternative anomalous
reading can be from cells loaded with too much BCECF. This
can result in an emission that reaches the maximum of the
instrument, and would give erroneous ratios. This is easily
prevented by loading less BCECF into the cells, either by
reducing the time, or by lowering the loading concentration.
An occasional examination of the individual emissions
wavelengths from each excitation wavelength can be used to
ensure this is not occurring. Nigericin is a Hþ, Kþ ionophore
used to calibrate pHi. Extensive washing of the coverslip
holder should be used to ensure that there is no trace
contamination with residual nigericin in future experiments.
When experiments are done with acutely treated cells, it is
usually permissible to compare simple changes in the rate of
pHi. However, when examining cells that have been chroni-
cally treated, or when comparing different cells lines this may
not be adequate. Buffering capacity of cells should be deter-
mined and proton flux calculated to ensure that the apparent
changes in pHi, are due to Na
þ/Hþ exchanger activity and not
due to changes in cell buffering. Measurement of cell buff-
ering and proton flux is described earlier [30].
2.2.6. Assessment of cell migration
The effect of NHE1 activity on cell migration can be
assessed with a wound-healing assay. Equal numbers of cells
(0.5  106) are seeded into multi-well plates (generally 12e24
well plates; greater starting numbers of cells can be plated for
6 well plates) and allowed to grow to confluence. A scratch
(wound) is induced in the monolayer with a pipette tip (which
can be facilitated by attached the tip to an aspirator). Culture
media is then aspirated and the wells are washed with 1X
phosphate-buffered saline (PBS) to remove unattached cells.
To assess NHE1 activity in triple-negative breast cancer cells,
serum starvation over 24 h is utilized to induce a hyper-
activation of exchanger activity. Control wells will contain
culture media with 10% serum, while serum-deprived wells
will contain media with only 0.2% serum. All other culture
conditions remain unchanged. At this stage, any chemical
agonists or inhibitors being tested can be introduced into
culture media at appropriate concentrations. A light micro-
scope with imaging software is required to take bright-field
images of the induced gap (wound) in the cell monolayer at
0 h. Imaging software should allow for arbitrary measurements
Fig. 2. Assessing effector functionality mediated by Naþ/Hþ exchanger activity in MDA-MB-231 cells. a, Cell migration assays. Rate of cell migration over time is
measured by rate of gap closure in a wound-healing assay. Imaging software can be used to take arbitrary measurements of gap distance to track gap closure and
compare between treatments. Here, NHE1 activity is upregulated by serum starvation (STIM, 0.2% serum), and the resultant increase in the rate of cell migration at
18 h can thus be quantified. b, Cell invasion assays. Rate of cell invasion through Matrigel® matrix-coated transwell inserts can be determined by quantifying the
numbers of stained invading cells attached to the underside of the transwell insert. For comparison, highly invasive MDA-MB-231 cells are shown with moderately
invasive MDA-MB-468 cells and non-invasive MCF-7 cells. c, 3-D cell invasion assays. Long-term invasion, growth and proliferation of cells can be assessed with
3-D culture over 7 days. Cells are seeded in transwell inserts fitted with Alvetex® scaffold membranes that allow for cell growth in three dimensions, emulating cell
growth and behavior in vivo. Here, we demonstrate the effect of NHE1 expression on long-term invasion where MDA-MB-231 cells expressing endogenous wild-
type NHE1 are able to traverse the scaffold and grow and proliferate within it, while cells lacking NHE1 are only minimally invasive and viable.
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36, 48 h) over time (Fig. 2a). A minimum of three wells per
treatment, three images per well, and three measurements per
image is required for a good representation of experimental
outcome over multiple independent experiments.
2.2.7. General considerations
Optimization experiments for cytotoxicity of any chemical
compounds, particular ion exchange inhibitors, should be
carried out prior to their use in cell-based assays. Ensure thatcell monolayers are not compromised and cells do not lift off
in response to treatment with drugs. If so, wells may need to
be coated with gelatin or poly-D-lysine prior to plating cells
to ensure maximal adherence to the plastic. When testing
multiple cell lines, rates of proliferation also need to be taken
into consideration. If some cells proliferate at a higher rate
than others, the rate of migration can be skewed by prolif-
eration of cells inducing gap closure. In this instance, using
mitomycin-C or another inhibitor of cell proliferation is
recommended.
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NHE1 activity is key in cell invasion that occurs through
the extracellular matrix [17]. In vitro, the ability of invasive
cells to digest through the extracellular matrix is tested with
transwell invasion assays, similar to a Boyden-chamber prin-
ciple. Sterile transwell permeable inserts (Costar®, Corning)
have polycarbonate membranes with 8 mm pores (pore size
varies according to cell type used), and are 6.5 mm in diameter
for a 24-well plate. Inserts are coated with Matrigel® Matrix
(BD Biosciences), a solubilized basement membrane prepa-
ration extracted from the Engelbreth-Holm-Swarm mouse
sarcoma that can be used to mimic the extracellular matrix
in vitro. Matrigel® matrix concentrations from manufacturer
can vary with batches; as such, optimization is necessary to
determine the concentration of matrix to coat inserts. We used
50 ml of a 1:10 dilution of 8.0 mg/ml concentration of
Matrigel® matrix to coat inserts. Equal cells numbers (gener-
ally 1  105 cells) are added to each matrix-coated insert in
0.2% serum-containing culture media; total volume of cell
suspension and matrix coating should not exceed 100 ml. Any
drugs being tested should be added to the cells at this point.
Inserts (upper chamber) are placed in reservoir wells (lower
chamber) of a 24-well plate. Each reservoir well should
contain up to 800 ml of complete media containing 10% serum
to induce cell movement through chemotaxis. Cells are incu-
bated for 24e48 h to determine their invasive capacity. Inva-
sive cells will digest through the matrix, and pass through the
pores, adhering to the underside of the polycarbonate mem-
brane of the insert, while non-invasive cells will remain in the
upper chamber. Post-invasion, media is removed from inserts
with a pipette and any non-invasive cells and matrix coating
are removed with a cotton swab. Inserts are washed twice in
PBS. Cells on the underside of inserts are then fixed by placing
them in another 24-well plate in wells containing 3.7% para-
formaldehyde for 2 min, prior to washing twice with PBS.
Cells are permeabilized by placing inserts in wells containing
100% ice-cold methanol for 20 min, prior to washing twice
with PBS. To stain cells, inserts are placed in wells containing
Giemsa for 15 min. Inserts are washed 2e3 times in PBS to
remove traces of dye and swabbed dry with a cotton bud. A
light microscope with imaging software is required to take
bright-field images of invasive cells (Fig. 2b). To visualize
cells, inserts can be imaged directly by placing them on a glass
slide, or the membrane can be excised using a scalpel and
mounted on a slide with suitable mounting media and a
coverslip. Imaging software can be used to count the number
of invading cells, or cells can be counted manually. A mini-
mum of three inserts per treatment, and three field images per
insert is required for a good representation of experimental
outcome over multiple independent experiments.
2.2.9. General considerations
Matrigel® matrix coating of inserts may need to be
standardized prior to running invasion assays. Several di-
lutions of Matrigel® may need to be tested depending on the
cell type used and the duration of the invasion assay. Inserts
(of the size specifications described above) should not becoated with more than 50 ml of matrix suspension. It is
recommended that any drugs being tested is added to media
in both upper and lower chambers to assess their impact on
invasion. Care should be taken in washing steps to minimize
loss of cells.
2.2.10. Assessment of 3-D cell invasion
The effect of NHE1 activity on cell invasion can be
assessed in the long term by using scaffold inserts that allow
cells to undergo 3-dimensional growth instead of the poly-
carbonate porous inserts described above, where cells grow in
a 2-dimensional monolayer. 3-D invasion assays utilize
Alvetex® scaffold inserts (Reinnervate, UK) in a multi-well
format. Here, sterile 6-well polystyrene scaffold inserts were
used. Alvetex® scaffolds have a thickness of 200 mm and are
highly porous. Prior to seeding cells, inserts were primed for
cell culture by soaking in 70% ethanol, washed in PBS, and
then coated with 0.8 mg/ml Matrigel® matrix per manufac-
turer's recommendations. 1  106 cells in a volume of 100 ml
of complete culture media was added to the top of scaffolds
and cells were allowed to adhere for 90 min prior to gently
flooding wells with media supplemented with 10% serum (up
to 10 ml per well in a 6-well format). Any drug treatments
should be added at this stage. Media should be changed every
2e3 days; invasion assays for MDA-MB-231 TNBC cells can
range from 7 to 21 days. For a study of long-term invasion
dependent on Naþ/Hþ exchange activity, 7 days is sufficient.
After this period, membrane scaffolds are excised from inserts
with a scalpel and embedded in paraffin, taking care to
maintain their top-to-bottom orientation so as to track cell
invasion through the insert. Embedded scaffolds are then
longitudinally sectioned into 10 mm thick slices, stained with
hematoxylin and eosin, and mounted on glass slides for
visualization with bright-field microscopy (Fig. 2c). Numbers
of invading cells can be counted for a semi-quantitative rep-
resentation of data. A minimum of three inserts per treatment,
and three field images per insert is required for a good rep-
resentation of experimental outcome over multiple indepen-
dent experiments.
2.2.11. General considerations
Over time, invasive cells seeded on top of inserts will
invade through the scaffold, growing and proliferating within
it. Non-invasive cells will show limited movement, growth and
proliferation within the scaffold (Fig. 2c). Hence, overall assay
duration needs to be optimized depending on cell type, espe-
cially if any drugs are used. Serum starvation is not recom-
mended for long-term experiments greater than 3 days.
3. Discussion
In this study, we describe several assays used for the
determination of NHE1-related activity in the triple-negative
breast cancer cell line MDA-MB-231. As noted above,
NHE1-mediated increase in pHi is associated with the prolif-
eration and transformation tumor cells [8e18] and NHE1 has
been shown to play a critical role in the growth and metastasis
22 S.R. Amith et al. / Biochimie Open 2 (2016) 16e23of TNBC cells [19e23]. Elucidation of the cause of elevated
NHE1 activity and the development of new and improved
potent and specific inhibitors of the protein are thus paramount
in treatment of the disease. These require characterization of
the activity of the protein and its induced downstream physi-
ological effects.
Assay of NHE1 activity in MDA-MB-231 cells is relatively
rapid. An experienced technician can complete over 20 assays
in one day. We have used the same procedures on other types
of breast cancer cells including hormone receptor-positive
MCF-7 and triple-negative MDA-MB-468 breast cancer
cells. There is no reason to believe that other similar cells
types cannot be similarly assayed in this manner. Furthermore,
the assessment of cell effector functions like directed migra-
tion and invasion is a key in determining the effects of novel
inhibitors of NHE1 activity in these cells. Here, we describe
assays to evaluate the rates of cell migration and invasion
using well-established methodologies that have been modified
specifically for triple-negative breast cancer cell lines. In
addition, we present a robust new method of assessing long-
term in vitro invasiveness, growth and proliferation of these
cells in 3-D culture that closely mimics cell growth and
behavior in vivo. We were the first to demonstrate that
knocking out NHE1 in MDA-MB-231 TNBC cells drastically
limits their capacity for long-term invasion in 3-D culture [19].
Testing the efficacies of novel NHE1 inhibitors in these assays
can therefore provide important knowledge prior to moving
into an in vivo animal model system.
In the search for therapies specifically aimed towards triple-
negative breast cancer, NHE1 provides a promising target.
NHE1 activity becomes dysregulated at the onset of oncogenic
transformation, arguably prior to, or concurrent with, the
altered metabolism of cancer cells associated with tumori-
genesis [4]. This dysregulation leads to cellular alkalinization
and extracellular acidification that promotes the establishment
of the tumor microenvironment. Recent evidence suggests that
the development of resistance seen with the use of chemo-
therapy drugs is facilitated by the acid pH of the tumor
microenvironment [32]. Routinely used chemotherapy drugs
are generally basic and become protonated and neutralized in
an acidic milieu, compromising their efficacy and ability to
reach intracellular targets. We have previously demonstrated
that, in MDA-MB-231 cells, selective inhibition of NHE1
activity with EMD87580 (2-methyl-4,5-di-(methylsulfonyl)-
benzoylguanidine) or HMA (5-(N, N-hexamethylene)-ami-
loride) increased the efficacy of paclitaxel-mediated cell death
[19]. These NHE1 inhibitors had a synergistic effect on
paclitaxel therapy, augmenting its anti-metastatic effects at
low doses. We conclude that the development of more potent
and specific NHE1 inhibitors that can modulate the pH of the
tumor microenvironment to prevent or limit cancer progres-
sion independent of chemotherapy drugs is an important and
necessary next step in anti-cancer therapeutics. The assays
described in this manuscript, give insights into the effects of
NHE1 inhibitors directly on NHE1 activity, and into its
downstream behavior promoting metastasis. They shouldprove most useful in testing novel NHE1 inhibitors for future
anti-metastatic use.
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